Floatz logo

Calaspargase Pegol

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Children's Oncology Groupprotein_peptidePhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

26 Active assets in the B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 cohort.

Asset / SponsorPhaseRating
METHOTREXATE
OHSU Knight Cancer Institute
Phase 2B
PREDNISONE TABLETS
University of Washington
Phase 2B
Blinatumomab
OHSU Knight Cancer Institute
Phase 2B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University of Washington
Phase 2B
Cyclophosphamide
University of Washington
Phase 2B

View all 29 →

Same molecule, other indications

Calaspargase Pegol is also rated in:

lymphoblastic lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Non-Small-Cell Lung (NSCLC)Dormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →